Pfizer (PFE) stock is a new Buy at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- Nvidia releases AI safety software it says could have stopped Hugging Face hack
- Trump says men arrested at UK air base used by US were looking to do 'big damage'
- Oppenheimer sees AI software winners as focus shifts to ROI
- Dollar near two-month high as US-Iran stalemate bolsters oil, Fed rate hike bets
- BofA Securities Starts IonQ, Inc. (IONQ) at Buy
Guggenheim Starts Pfizer (PFE) at Buy, 'Successful Execution Can Drive Upside'
February 22, 2024 4:10 PM EST(Updated - February 23, 2024 4:04 AM EST)
Guggenheim analyst Vamil Divan initiates coverage on Pfizer (NYSE: PFE) with a Buy rating and a price target of $36.00.
The analyst comments "We are initiating coverage on Pfizer Inc. (PFE) with a BUY rating and $36 price target. Pfizer shares have significantly underperformed... More
